The "High Solubility" Definition of the Current FDA Guidance on Biopharmaceutical Classification System May Be Too Strict for Acidic Drugs

Pharmaceutical Research

Volumn 21, Issue 2, 2004, Pages 293-299

  Yazdanian, Mehran ^a   Briggs, Katherine ^a   Jankovsky, Corinne ^a   Hawi, Amale ^b  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b A Hawi Consulting Ltd   (United States)

Author keywords

Biopharmaceutical Classification System (BCS); Caco 2; Permeability; Solubility

Indexed keywords

ACETIC ACID DERIVATIVE; ACETYLSALICYLIC ACID; ATENOLOL; CAFFEINE; CELECOXIB; DICLOFENAC; ETODOLAC; FENAMIC ACID DERIVATIVE; FENOPROFEN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MANNITOL; MEFENAMIC ACID; METOPROLOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; OXICAM DERIVATIVE; PROPIONIC ACID DERIVATIVE; PROPRANOLOL; RANITIDINE; ROFECOXIB; SULINDAC; TOLMETIN; UNINDEXED DRUG; VERAPAMIL;

ACIDITY; ALKALINITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DRUG CLASSIFICATION; DRUG DETERMINATION; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG UPTAKE; EQUILIBRIUM CONSTANT; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; LOW DRUG DOSE; PRIORITY JOURNAL;

ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CACO-2 CELLS; HUMANS; PERMEABILITY; SOLUBILITY; TERMINOLOGY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 1242337282     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000016242.48642.71     Document Type: Article

References (21)

1. G. L. Amidon, H. Lennernas, V. P. Shah, and J. R. Crison. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:413-420 (1995).
2. Guidance for Industry, Immediate Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes, November 1995, FDA/CDER.
3. Guidance for Industry, Waiver of In Vivo Bioavailability and Bioequivalence studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, August 2000, FDA/CDER.
4. L. X. Yu, G. L. Amidon, J. E. Polli, H. Zhao, M. Mehta, D. P. Conner, V. P. Shah, L. J. Lesko, M-L. Chen, V. H. L. Lee, and A. S. Hussain. Biopharmaceutics Classification System: the scientific basis for biowaiver extension. Pharm. Res. 19:921-925 (2002).
5. E. Galia, E. Nicolaides, D. Horter, R. Lobenberg, C. Reppas, and J. B. Dressman. Evaluation of various dissolution media for predicting in vivo performance of Class I and Class II drugs. Pharm. Res. 15:698-705 (1998).
6. The United States Pharmacopoeia (USPXXIII). United States Pharmacopoeia Convention, Inc., Rockville, MD, 1995.
7. E. Galia, J. Horton, and J. B. Dressman. Albendazole generics - a comparative in vitro study. Pharm. Res. 16:1871-1875 (1999).
8. M. Yazdanian, S. L. Glynn, J. L. Wright, and A. Hawi. Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm. Res. 15:1490-1494 (1998).
9. Drug Facts and Comparisons, 54th ed., Facts and Comparisons, St. Louis, MO, 2000.
10. E. Liang, J. Proudfoot, and M. Yazdanian. Mechanisms of transport and structure-permeability relationship of sulfasalazine and its analogs in Caco-2 cell monolayers. Pharm. Res. 17:1168-1174 (2000).
11. M. Hammarlund-Udenaes and L. Z. Benet. Furosemide pharmacokinetics and pharmacodynamics in health and disease - an update. J. Pharmcokin. Biopharm. 17:1-46 (1989).
12. J. G. Hardman, L. E. Limbird, R. W. Ruddon, and A. G. Gilman (eds.), Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed., McGraw Hill, New York, 1996.
13. P. Macheras and P. Argyrakis. Gastrointestinal drug absorption: is it time to consider heterogeneity as well as homogeneity? Pharm. Res. 14:842-847 (1997).
14. L. X. Yu, A. S. Carlin, and A. S. Hussain. Feasibility studies of intrinsic dissolution rate as an alternative method to determine BCS solubility membership. AAPS annual meeting (2000).
15. M. J. Ginski, R. Taneja, and J. E. Polli. Prediction of dissolution-absorption relationships from a continuous dissolution/Caco-2 system, AAPS Pharmsci. 1: article 3 (1999). Available: http:// www.pharmsci.org.
16. D. B. Jack. Handbook of Clinical Pharmacokinetic Data, Macmillan Publishers Ltd., New York, 1992.
17. Physician's Desk Reference, 55th ed., Medical Economic Co., Montvale, NJ, 2001.
18. P. Artursson and J. Karlsson. Correlation between oral drug absorption in humans and apparent drug permeability coefficient in human intestinal (Caco-2) cells. Biochim. Biophys. Res. Commun. 175:880-885 (1991).
19. The Merck Index, 12th ed., Merck & Co., Inc., Whitehouse Station, NJ, 1996.
20. D. E. Duggan, L. E. Hare, B. A. Ditzler, B. W. Lei, and K. C. Kwan. The disposition of sulindac. Clin. Pharm. Ther. 21:326-335 (1976).
21. th ed., McGraw Hill, New York, 2001.